Synergism between Angiotensin receptors ligands: Role of Angiotensin-(1-7) in modulating AT2 R agonist response on nitric oxide in kidney cells

Pharmacol Res Perspect. 2020 Dec;8(6):e00667. doi: 10.1002/prp2.667.

Abstract

Angiotensin-(1-7), an endogenous agonist for the MasR, has been shown to interact with ang-II AT1 R and AT2 R. Earlier we showed a physical and functional interaction between MasR and AT2 R in response to their respective agonists ang-(1-7) and C21. Moreover, ang-(1-7) is cardio-protective via AT1 R and alters ang-II function. Such complex nature of ang-(1-7) function is not clearly understood, particularly in relation to its functional interaction with these receptors. We tested how ang-(1-7) affects AT2 R function by utilizing HK-2 cells. The HK-2 cells were treated with a wide range of concentrations of angiotensin receptor agonists. The generation of NO in response to agonists was determined as a readout and subjected to Bliss definition (δ score) to assess the nature of functional interaction between these receptors. Preincubation with ang-(1-7) followed by incubation with endogenous AT1 R/AT2 R agonist ang-II (δ = 162) or selective AT2 R agonist C21 (δ = 304) synergized NO formation. The synergism was also observed when the order of incubation with ang-(1-7)/C21 was reversed (δ = 484), but not when the cells were simultaneously incubated with a mixture of ang-(1-7) and C21 (δ = 76). The synergism with nonpeptidic MasR agonist AVE0991 followed by C21 (δ = 45) was minimal. Ligand binding experiment suggested the binding of ang-(1-7) with these three receptors. However, the synergism observed with ang-(1-7) and ang-II/C21 was sensitive to the antagonists of AT2 R (PD123319) and AT1 R (candesartan), but not MasR (A779). Ang-(1-7) at lower concentrations synergies the AT2 R function in an AT1 R-dependent but MasR-independent manner. This phenomenon may have a physiological significance.

Keywords: angiotensin receptor; epithelial cells; nitric oxide; receptor mas; synergism.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Angiotensin I / administration & dosage*
  • Angiotensin II / administration & dosage
  • Cell Line
  • Dose-Response Relationship, Drug
  • Drug Synergism
  • Humans
  • Kidney / cytology*
  • Kidney / drug effects
  • Kidney / metabolism*
  • Ligands
  • Nitric Oxide / metabolism*
  • Peptide Fragments / administration & dosage*
  • Proto-Oncogene Mas
  • Proto-Oncogene Proteins / agonists
  • Proto-Oncogene Proteins / metabolism*
  • Receptor, Angiotensin, Type 2 / agonists
  • Receptor, Angiotensin, Type 2 / metabolism*
  • Receptors, G-Protein-Coupled / agonists
  • Receptors, G-Protein-Coupled / metabolism*

Substances

  • Ligands
  • MAS1 protein, human
  • Peptide Fragments
  • Proto-Oncogene Mas
  • Proto-Oncogene Proteins
  • Receptor, Angiotensin, Type 2
  • Receptors, G-Protein-Coupled
  • Angiotensin II
  • Nitric Oxide
  • Angiotensin I
  • angiotensin I (1-7)